GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sysmex Corp (TSE:6869) » Definitions » COGS-to-Revenue

Sysmex (TSE:6869) COGS-to-Revenue : 0.48 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Sysmex COGS-to-Revenue?

Sysmex's Cost of Goods Sold for the three months ended in Mar. 2024 was 円64,262 Mil. Its Revenue for the three months ended in Mar. 2024 was 円134,985 Mil.

Sysmex's COGS to Revenue for the three months ended in Mar. 2024 was 0.48.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sysmex's Gross Margin % for the three months ended in Mar. 2024 was 52.39%.


Sysmex COGS-to-Revenue Historical Data

The historical data trend for Sysmex's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sysmex COGS-to-Revenue Chart

Sysmex Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.49 0.48 0.47 0.47

Sysmex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.47 0.48 0.47 0.48

Sysmex COGS-to-Revenue Calculation

Sysmex's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=219013 / 461510
=0.47

Sysmex's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=64262 / 134985
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sysmex  (TSE:6869) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sysmex's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 64262 / 134985
=52.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Sysmex COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sysmex's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sysmex (TSE:6869) Business Description

Traded in Other Exchanges
Address
1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, JPN, 6510073
Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.

Sysmex (TSE:6869) Headlines

No Headlines